No publications last week or this week. I’m happy to share any other publications from this week that I’ve missed – just let me know. I publish these updates weekly, on a Tuesday, but only if I’ve seen relevant publications. If you don’t see an update on a Tuesday, assume it has been a quiet week for publications in health economics and genomics!

Three publications from the past week:

• A three-year follow-up study evaluating clinical utility of exome sequencing and diagnostic potential of reanalysis | link
• Clinical Utilization, Utility, and Reimbursement for Expanded Genomic Panel Testing in Adult Oncology | link
• Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients | link

I’m happy to share any other publications from this week that I’ve missed – just let me know. I publish these updates weekly, on a Tuesday, but only if I’ve seen relevant publications. If you don’t see an update on a Tuesday, assume it has been a quiet week for publications in health economics and genomics!

Two publications from the last week:

• Efficacy and economics of targeted panel versus whole exome sequencing in 878 patients with suspected primary immunodeficiency | link
• Genomic Testing for Relapsed and Refractory Lymphoid Cancers: Understanding Patient Values | link

I’m happy to share any other publications from this week that I’ve missed – just let me know.

One publication from the last week:

• The value of genomic sequencing in complex pediatric neurological disorders: a discrete choice experiment | link

I’m happy to share any other publications from this week that I’ve missed – just let me know.

One publication this week:

• Next generation use in Oncology, a better information on patients’ genetic profiles improved access to matched treatments and earlier NGS use show better outcomes | link

I’m happy to share any other publications from this week that I’ve missed – just let me know.

Three publications this week:

• PARC report: health outcomes and value of personalized medicine interventions: impact on patient care | link
• The Daunting Economics of Therapeutic Genome Editing | link
• Cost-effectiveness analysis of pharmacogenomics-guided clopidogrel treatment in Spanish patients undergoing percutaneous coronary intervention | link

I’m happy to share any other publications from this week that I’ve missed – just let me know.

No publications last week, but five (well, kind of) this week:

• Costs of In-House Genomic Profiling and Implications for Economic Evaluation: A Case Example of Non-Small Cell Lung Cancer (NSCLC) | link
• Multi-gene Assays: Effect on Chemotherapy Use, Toxicity and Cost in Estrogen Receptor-Positive Early Stage Breast Cancer | link
• Ending the Diagnostic Odyssey—Is Whole-Genome Sequencing the Answer? | link
• Economic Value of Exome Sequencing for Suspected Monogenic Disorders [letter] | link
• Response to Ferket Et Al [response to letter] | link

I’m happy to share any other publications from this week that I’ve missed – just let me know.